A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 5000
Summary
- Conditions
- Comparative Effectiveness of Glycemia-lowering Medications
- Type 2 Diabetes
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 30 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01794143
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- National Heart, Lung, and Blood Institute (NHLBI)
- Becton, Dickinson and Company
- Bristol-Myers Squibb
- Merck Sharp & Dohme Corp.
- Novo Nordisk A/S
- Roche Diagnostics
- Sanofi
- Investigators
- Study Chair: David M Nathan, MD Massachusetts General Hospital
Get Well Soon